Previous 10 | Next 10 |
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 20, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the Company’s prev...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 6, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it plans to change the rat...
--News Direct-- Addex Therapeutics co-founder and CEO Tim Dyer speaks to Thomas Warner from Proactive about the work that the central nervous system-focused clinical-stage pharmaceutical company has been doing in the promising area of allosteric modulation. He explains that company is...
Addex led consortium wins Eurostar s grant to deliver clinical candidates to treat mild neurocognitive disorder s Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 20, 202 3 - Addex T...
Geneva, Switzerland, September 6 , 202 3 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Tim Dyer, Chief Executive Officer, will be attending ...
Cohort 1 is completed , and Cohort 2 is 80% recruited Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 5 , 202 3 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical compan...
Landmark study shows mGlu5 receptor negative allosteric modulators (NAMs) restore lost neurological functions First time mGlu5 linked to post - stroke functional recovery Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerla...
2023-08-10 21:48:03 ET Addex Therapeutics Ltd (ADXN) Q2 2023 Results Conference Call August 10, 2023 10:00 AM ET Company Participants Tim Dyer - Chief Executive Officer Robert Lutjens - Head of Discovery-Biology Mikhail Kalinichev - Head of Transition Science ...
2023-08-10 01:22:22 ET Addex Therapeutics press release ( NASDAQ: ADXN ): Q2 GAAP EPS of -CHF 0.04. During the second quarter of 2023, income increased by CHF 0.4 million to CHF 0.6 million compared to CHF 0.2 million in the second quarter of 2022. Cash and cash e...
ADX71149 Phase 2 e pilepsy c linical s tudy Cohort 2 continues recruiting following the Independent Interim Review Committee (IRC) recommendation Indivior GABAB PAM collaboration extended to June 2024 with CHF 2.7 million of committe...
News, Short Squeeze, Breakout and More Instantly...
Addex Therapeutics Ltd Company Name:
ADXN Stock Symbol:
NASDAQ Market:
Addex Therapeutics Ltd Website:
2024-07-19 15:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological...
Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that Mikhail Kalinichev, Head of T...